1. Home
  2. VIVS vs LNAI Comparison

VIVS vs LNAI Comparison

Compare VIVS & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VivoSim Labs Inc.

VIVS

VivoSim Labs Inc.

N/A

Current Price

$0.16

Market Cap

2.1M

Sector

Health Care

ML Signal

N/A

LNAI

Lunai Bioworks Inc.

HOLD

Current Price

$0.17

Market Cap

2.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VIVS
LNAI
Founded
2007
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1M
2.1M
IPO Year
2010
2014

Fundamental Metrics

Financial Performance
Metric
VIVS
LNAI
Price
$0.16
$0.17
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 721.4K
210.5K
Earning Date
11-13-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 1.85
EPS
★ N/A
N/A
Revenue
★ $4,603,000.00
$51,992.00
Revenue This Year
$228,144.28
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 8.82
N/A
52 Week Low
$0.14
$0.15
52 Week High
$3.40
$5.02

Technical Indicators

Market Signals
Indicator
VIVS
LNAI
Relative Strength Index (RSI) 37.34 13.57
Support Level N/A N/A
Resistance Level $0.30 $1.65
Average True Range (ATR) 0.02 0.10
MACD 0.00 -0.02
Stochastic Oscillator 36.23 0.49

Price Performance

Historical Comparison
VIVS
LNAI

About VIVS VivoSim Labs Inc.

VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques.

About LNAI Lunai Bioworks Inc.

Lunai Bioworks Inc is an AI-driven biotechnology company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or lifelong cancer remission in some of the deadliest cancers. The Group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. Its reportable segments are BioSymetrics, which derives the maximum revenue, and RENB. Geographically, the Group operates in the United States and Canada.

Share on Social Networks: